Fig. 2

In vitro formation of riBFU-E and mature riRBC from riHSC. The formed riHSC from the stem cells will then be treated with several in vitro growth and differentiation factors like GM-CSF, M-CSF, IL-3, SCF, TPO etc. to obtain BFU-E having HIV receptor-co-receptor complex. Then, these riBFU-E cells will be selected and isolated from other cell lineages by FACS using CD45⁺GPA⁻IL-3R⁻CD34⁺CD36⁻CD71⁺ markers to finally yield pool of pure riBFU-E cells. Another large population of cells having mixed population of riBFU-E and other lineages like lymphoid and myeloid cells will be treated by EPO to finally obtain only mature riRBC. GM-CSF granulocytemacrophage colony stimulating factor, M-CSF macrophage colony-stimulating factor, IL-3 interleukin-3, IL-11 interleukin-11, SCF stem cell factor, TPO thrombopoietin, FLT-3L Fms-related tyrosine kinase 3 ligand, CMP common myeloid progenitor, MEP megakaryocyte/erythrocyte progenitor, BFU-E burst forming unit-erythroid, riRBC receptor integrated red blood corpuscle, FACS fluorescence-activated cell sorting, riBFU-E receptor integrated burst forming unit-erythroid, EPO erythropoietin